X3b00356a.e947.42f1.8b5f.6dcd789d9272
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.350
- KRAS_SIGNALING_DN+0.320
- HEDGEHOG_SIGNALING+0.280
- NOTCH_SIGNALING+0.220
- ESTROGEN_RESPONSE_EARLY+0.180
- WNT_BETA_CATENIN_SIGNALING+0.170
- BILE_ACID_METABOLISM+0.140
- MYOGENESIS+0.130
- TGF_BETA_SIGNALING+0.110
- CHOLESTEROL_HOMEOSTASIS+0.090
Top 10 suppressed
- E2F_TARGETS-0.610
- MYC_TARGETS_V1-0.590
- G2M_CHECKPOINT-0.540
- INTERFERON_ALPHA_RESPONSE-0.510
- OXIDATIVE_PHOSPHORYLATION-0.500
- INTERFERON_GAMMA_RESPONSE-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.440
- DNA_REPAIR-0.420
- MTORC1_SIGNALING-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_YNEQJ6AH | DNET | — | 0.913 |
| 2 | SRR8613714 | — | A | 0.898 |
| 3 | SRR8518437 | — | D | 0.898 |
| 4 | MNG491 | — | — | 0.893 |
| 5 | MNG4 | — | — | 0.891 |
| 6 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.890 |
| 7 | BS_9RT63JD9 | low-grade glioma | — | 0.888 |
| 8 | C3L-00444 | — | cohortA1 | 0.887 |
| 9 | TCGA-56-8624-01A-11R-2403-07 | — | cohortSQ1 | 0.881 |
| 10 | TCGA-55-8616-01A-11R-2403-07 | — | cohortA1 | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |